Enabling Success in Rare Disease Clinical Trials
Rare disease clinical trials pose unique challenges for research sites, sponsors, and patients alike. With smaller patient populations, complex logistics, and specialized treatments, success requires thoughtful planning, collaboration, and flexibility.
Drawn from industry best practices, these strategies help rare disease trials succeed.
1. Make Collaborative Planning a Priority
Rare disease trials often involve complex protocols, stringent eligibility criteria, and small patient pools. For these trials to succeed, a collaborative relationship between clinical sites and sponsors is essential.
Inclusion and exclusion criteria should be carefully reviewed to avoid unnecessarily excluding patients from an already small pool of eligible participants. Additionally, contingency plans should be put in place in case of any logistical challenges.
At the same time, clinical sites must be proactive in communicating challenges and proposing solutions. This might involve recommending the use of decentralized trial elements and other variables to make participation easier for patients.
Proper resourcing is also critical. Sites must have adequate resources—sufficient staff, equipment, and support—to handle intricate trial protocols and patient needs effectively in rare disease trials. By ensuring clinical sites have the infrastructure, personnel, and technological tools, sponsors can prevent delays and inefficiencies.
2. Partner With Advocacy Groups and Registries and Online Communities
When it comes to recruiting patients for rare disease trials, consider engaging with patient advocacy organizations and disease registries. These organizations can help raise awareness about trials and connect sites with individuals who might otherwise be unaware of the opportunity.
Consider the case of a trial related to erythropoietic protoporphyria (EPP). EPP is a rare genetic disorder that affects only 4,000 to 6,000 individuals in the United States. Given the limited number of patients, clinical sites can turn to a resource like the Porphyria Registry Service for recruitment support.
Through this type of collaboration, clinical sites can access a highly engaged community of patients, offering a direct line to potential study participants.
Social media platforms, disease-specific forums, and patient-centric apps are also valuable resources for recruitment and engagement. Researchers can connect with these digital communities before, during, and after a study to raise awareness about trials and get direct feedback from patients.
3. Provide Travel Concierge Services
Geographic location is one of the biggest hurdles when working with rare disease populations. Patients often need to travel long distances to participate in trials, which can be a significant burden.
Clinical sites can mitigate this challenge by partnering with sponsors to simplify travel coordination. When sponsors and sites work together to handle arranging a patient’s flights, accommodations, and ground transportation, it removes logistical stresses that make it easier for patients to participate in the trial. By eliminating these barriers, sites ensure that distance does not become a disqualifying factor.
4. Adopt a Patient-Centric Approach
It’s also important to acknowledge what you’re asking of patients. When patients must travel great distances or make other significant sacrifices to participate, clinical sites should ensure the experience is as accommodating and supportive as possible.
Providing travel plans well in advance allows participants to organize their schedules, secure time off work, and make necessary personal arrangements. Offering flexible appointment times, including weekends and evenings, further demonstrates respect for their time and commitment.
As rare disease trials often require repeated visits, it’s vital to maintain open, empathetic communication. When unforeseen circumstances arise, such as abnormal lab results, patients should not be burdened with additional travel unless absolutely necessary. Instead, sites should explore alternatives, such as using home health services for routine procedures like blood draws to reduce the inconvenience for patients.
5. Build Relationships for Long-Term Retention
Patients with rare diseases are often motivated by more than just the potential benefits of the trial; they frequently want to contribute to advancing treatment for their condition. Clinical sites should leverage this motivation by fostering positive relationships that encourage referrals and long-term engagement.
Creating an exceptional patient experience leads to higher retention rates, and even the potential for referrals. When patients feel supported, they are more likely to refer friends, family members, or others in their community to participate in future studies at a site.
Offering clear communication, flexible scheduling, and personalized care throughout the trial helps to build trust. This is critical for patient retention in any clinical trial—especially in rare disease research, where every participant counts.
6. Utilize Expanded Access Programs
Expanded Access Programs (EAPs) allow patients who are not eligible for clinical trials to access experimental treatments outside the trial environment. Offering EAPs as a component of your rare disease research strategy can increase visibility and engagement while providing treatment options for patients ineligible for trials. This also helps sponsors gather additional safety and efficacy data in a real-world setting.
7. Offer Genetic Testing and Counseling
Rare diseases are often genetic, and many patients may be unaware of their specific diagnosis. Providing genetic testing and counseling services can help identify eligible patients and ensure they fully understand their condition and the potential impact of participating in a clinical trial. This is particularly valuable for diseases that may have multiple genetic variants.
Driving Success in Rare Disease Research
Successfully conducting rare disease clinical trials requires a strategic, patient-focused approach that goes beyond standard practices. Clinical sites that prioritize the needs of patients—through tailored support, logistical solutions, and strong partnerships—are better positioned to overcome the unique challenges posed by rare disease studies. From working with advocacy groups to streamline recruitment, to offering flexible travel accommodations, these elements support patient engagement and overall trial success.
At the same time, clinical sites need to have the right resources. With the necessary infrastructure and tools available to conduct efficient, patient-friendly studies, well-equipped sites are better positioned to manage the complexities of rare disease trials.
For deeper insights into how clinical sites can refine their approach to rare disease trials, stream this recent SCRS podcast episode.
By Hamish Baird, President & CEO, Remington-Davis
